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mates for virological response (VR; viral load levels50 copies/ml), immunorecov-
ery (change in CD4 cells/l from baseline to week 96), incidence of diarrhea, nausea
and rash were generated by Bayesian mixed treatment comparison (MTC). Point
estimates were reported with corresponding 95% credible intervals. RESULTS: In
total, 6 unique studies and 2 study extensions were included; consisting of 3 ATV/r,
1 DRV/r, 5 LPV/r, and 5 EFV treatment arms. Pooled MTC estimates for VR at week
48 were 77.7% (95%CrI: 74.1%-81.1%) for ATV/r, 76.4% (72.9%-79.7%) for EFV, 74.7%
(67.2%-81.2%) for DRV/r, and 72.5% (69.9%-75.0%) for LPV/r. The ratio of the propor-
tion of patients with VR at week 96 versus week 48 was estimated at ATV/r: 0.934
(0.872-0.999), DRV/r: 0.918 (0.807-1.041), EFV: 0.908 (0.834-0.981) and LPV/r: 0.878
(0.827-0.929). Immunorecovery was 254.9 (245.2-264.9) cells/l for LPV/r, 238.1
(219.5-257.0), 225.2 (209.6-241.3), and 206.1 (190.3-222.4) for DRV/r, ATV/r and EFV
respectively. The incidence of diarrhea was 10.7% (8.7%-12.8%) for LPV/r, compared
to 4.5% (2.3%-7.4%), 2.3% (0.3%-7.0%), and 2.1% (1.0%-3.7%) for DRV/r, EFV, and
ATV/r respectively. The incidence of nausea and rash did not differ markedly
among the treatments. CONCLUSIONS: The estimates for efficacy and tolerability
suggest all 4 ARV treatments are valuable options in treatment-naive HIV patients,
with ATV/r’s sustained viral response bringing added value. This MTC provides a
useful framework for ARV treatment comparison for HTA and clinical decision
making.
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OBJECTIVES:To systematically assess the clinical and economic burden of invasive
fungal infection (IFI) in Europe and to understand the value and treatment out-
comes of diagnostic and empirical therapeutic approaches. METHODS: A compre-
hensive literature review was conducted using PubMed/MEDLINE and EMBASE
(past 10 years) and relevant clinical societies (last 5 years) to identify epidemiology,
outcomes, and treatment trends focusing on invasive Aspergillus and Candida
infections using a defined protocol for inclusion/exclusion and data collection met-
rics. Clinical and economic burden outcomes described were incidence, mortality,
overall healthcare resource utilization, length of hospital stay, and costs for IFI.
RESULTS: Of 370 abstracts screened, 57 primary literature articles and 18 clinical
society abstracts met inclusion criteria providing data from 12 European countries.
No studies were identified in Eastern Europe and only two randomized, controlled
studies comparing pre-emptive to empirical treatment were found. IFI incidence
ranged from 3%-8% in empirical vs 8%-9% in pre-emptive treatment. Overall (IFI
attributable) mortality ranged from 5%-41% (0%-24%) and 2%-17% (0%-13%) for
non-comparative vs comparative studies, respectively. The highest mortality was
found among critically ill patients, pediatric, and those with hematologic malig-
nancies. The cost of IFI ranged from €8,351-€11,821 when evaluating hospitaliza-
tions and antifungals to €26,596-€49,216 when all direct costs for management
were included. Costs for antifungal therapy alone were €3,930-€7,314. The incre-
mental cost burden of IFI ranged from €10,530-€51,033 depending on the certainty
of infection (possible, probable, proven) and duration of follow up. CONCLUSIONS:
IFI represents a substantial clinical and economic burden in critically ill and im-
munocompromised patients in Europe. IFI may account for up to 24% of mortality
in these high risk populations and increase length of hospitalization by 20%. Dif-
ferentiation of outcomes for pre-emptive and empirical treatment strategies have
not been well defined and should be the focus of future clinical studies.
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OBJECTIVES: The aim of the study was to conduct secondary analyses of trial data
to determine whether taking famciclovir within 12 hours of first perceiving the
symptoms of genital herpes was related to decreased outbreak severity and im-
proved healing. METHODS: Data were derived from a double-blind, randomised,
active-controlled study of patient-initiated therapy comparing a 2-day course of
famciclovir with a 5-day course (total dose 1,50 mg in both courses) in adults with
genital herpes. Patients completed the Herpes Symptoms Checklist (HSC) on each
day of the five day study period. The proportion of patients healed (without lesions)
at day 5 was also determined. RESULTS: Data were available for 501 patients
(male  58.5%; mean age (sd)  39.2 (11.6) yrs). For the combined treatment
groups, patients who took their medication within 12 hours had significantly
lower HSC scores on day 1 (within 12 hours, median HSC6; above 12 hours,
median HSC8; Mann-Whitney U12,733.5, p0.05). Patients who took their
medication within 12 hours also had significantly lower HSC area under the
curve scores for the 5 day study period (AUC; within 12 hours, median HSC3.8;
above 12 hours, median HSC5.1; Mann-Whitney U12,751.0, p0.05). These
differences were not apparent for the treatment groups separately. There was a
significant association between the time at which the patients took their med-
ication and whether or not they were healed at day 5 for the combined sample
(Chi-square  4.95, p0.05). This finding was also observed for the 2-day treat-
ment group (Chi-square6.11, p 0.05) but not for the 5-day treatment group
(Chi-square0.49, p0.48). CONCLUSIONS: Taking famciclovir within 12 hours of
first becoming aware of genital herpes symptoms is associated with decreased
symptom severity and speed of healing. The 2-day treatment, when taken within
12 hours, is associated with a higher rate of healing by day 5.
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OBJECTIVES: In Turkey, lamivudine (LAM) is the only reimbursed antiviral (AV)
agent for the treatment of chronic hepatitis B (CHB) patients with HBV-DNA level
107 copies/mL. According to local reimbursement guideline, Tenofovir (TDF)
should be added in case of non-response at week24, or when viral resistance is
observed. This study aimed to compare the long-term clinical outcomes of enteca-
vir (ETV) with the current reimbursement approach (LAM monotherapy or LAM
with add-on TDF as rescue) in this patient subgroup. METHODS: Analysis popula-
tion included patients (n1000; 35% HBeAg-positive; 35 years old) without com-
pensated or decompensated cirrhosis (CC or DC) or hepatocellular cancer (HCC) at
model entry. Daily dose of AVs compared were (1) ETV 0.5mg, (2) LAM 100mg and (3)
LAM 100mg  add-on TDF 300mg when non-response or viral resistance occurs. A
decision-tree model with 5 parallel pathways for different levels of HBV-DNA with
a time horizon of 10 years was built. Major clinical outcomes included mortality
and life-years lost (LYL). RESULTS: Monotherapy with LAM during 10 years, re-
sulted in 198CC, 8.9DC and 66HCC cases . Addition of TDF to LAM in case of non-
response or viral resistance, reduced these cases to 78, 3.6 and 24 patients, respec-
tively. ETV treatment resulted in 24, 0.9 and 7.5 avoided cases of CC, DC and HCC,
respectively. While 108 deaths are estimated with LAM monotherapy (1,916LYL), in
the LAM plus TDF approach, the number of death will decrease to 44 (794LYL). ETV
treatment will further improve the results with additional avoidance of 15 deaths
(275LYL). The advantage of ETV is more prominent in HBeAg-positive patients (444
avoided LYL). CONCLUSIONS: ETV was found to be superior to both LAM mono-
therapy and LAM add-on TDF approaches in the treatment of CHB. Better clinical
outcomes may be expected with the introduction of ETV in this subgroup.
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OBJECTIVES: To indirectly compare the efficacy of telaprevir and boceprevir com-
bined with peginterferon/ribavirin in achieving sustained viral response (SVR) in
treatment-naïve and treatment-experienced patients with genotype 1 chronic
hepatitis C virus (HCV). METHODS: A systematic review of literature was con-
ducted in MEDLINE (January 2000-December 2010) to identify randomized con-
trolled trials and comparative open-label studies on the efficacy of pegylated inter-
feron (-2a and -2b)-ribavirin (PR)-based treatment in genotype 1 chronic HCV
patients. A Bayesian mixed treatment comparison (MTC), enabling indirect com-
parisons of interventions while respecting randomization, was performed on the
endpoint of SVR (HCV RNA undetectable at 24 weeks after end of treatment), as-
suming fixed study effects. For treatment-experienced patients, only previous re-
lapsers and partial responders were included, as no clinical results in prior null-
responders were available for boceprevir. RESULTS: Twelve publications were
identified and included in the systematic review and MTC. In treatment-naïve
patients, the odds ratio (OR) (posterior mean [95% credible interval]) for telaprevir
(12 weeks Response Guided Treatment (RGT) 24/48 weeks PR) and boceprevir (24
weeks  RGT 28/48 weeks PR) versus PR was respectively 3.76 [2.78-5.22] and 2.96
[2.23-4.01]. The OR for the indirect comparison of telaprevir versus boceprevir was
1.46 [0.89-2.25] (probability(OR1)0.931). In treatment-experienced patients, the
OR of telaprevir (12 weeks  48 weeks PR) and boceprevir (32 weeks  RGT 36/48
weeks PR) versus PR was respectively 12.56 [7.30-24.43] and 5.12 [2.90-10.30]. The OR
for the indirect comparison of telaprevir versus boceprevir was 2.70 [1.02-5.80]
(probability(OR1)0.978) for all patients, and 3.63 [1.12-8.97] and 1.39 [0.08-6.05]
for prior relapsers and partial responders respectively. CONCLUSIONS: In the ab-
sence of direct comparative head-to-head studies between telaprevir versus boce-
previr for the treatment of chronic HCV genotype 1 patients, MTC-based indirect
comparison suggests better efficacy for telaprevir in both treatment-naïve and
treatment-experienced patients compared to RGT boceprevir.
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OBJECTIVES: In Turkey, lamivudine (LAM) is the only reimbursed antiviral (AV)
agent for the treatment of chronic hepatitis B (CHB) patients with HBV-DNA level
107 copies/mL. Tenofovir (TDF) can be added when the patient does not respond at
week24, or viral resistance emerges. This study aimed to compare the long-term
clinical outcomes of telbivudine (ldt) with or without TDF add-on and LAM with or
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without TDF add-on in the treatment of CHB. METHODS: Analysis population con-
sisted of patients (n1000; 35% HBeAg-positive; 35 years old) without compensated
or decompensated cirrhosis(CC, DC) or hepatocellular cancer(HCC). AVs compared
were 1) Ldt 600mg/day; 2) Ldt add-on TDF 300mg/day when non-response or viral
resistance occurs; and 3)LAM 100mg/day (4)LAM add-on TDF 300mg/day. A deci-
sion tree model with 5 parallel pathways for different levels of HBV-DNA was built
using a 10-year time-horizon. Selected major clinical outcomes were mortality and
life-years-lost (LYL). RESULTS: With LAM or Ldt monotherapy, 137CC, 5DC, 40 HCC
cases and 70 dead versus 85CC, 3,5DC and 25HCC cases and 44 dead were expected
to occur, respectively. With LAM or Ldt monotherapy, 1236 and 774 life-years will
be lost, respectively. When a potent AV is added to LAM or Ldt, HBV complications
were expected to decrease and avoided LYL were substantial (164 to 591 years,
respectively). However, there is no important difference between starting with
LAM or Ldt and adding TDF strategies: 1CC, 0 DC, 0HCC cases and 2 dead will be
avoided. CONCLUSIONS: Ldt monotherapy was found to be superior to LAM mono-
therapy. However, Ldt TDF does not seem a better approach than LAMTDF in
the treatment of CHB. This paradoxical finding might be explained due to margin-
ally superior efficacy of Ldt versus LAM and a longer time-period before adding a
potent antiviral to treatment.
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OBJECTIVES: Chronic Hepatitis C virus (HCV) infection is one of the silent global
epidemics with significant unmet need and disease burden. One of the major lim-
itations of current treatments is the need for 12 or 6 months of Interferon based
therapy, which has tolerability and toxicity issues for many patients. During last
2-3 years several new agents have been tested in clinic, which have shown prom-
ising results as non-interferon based therapy. Goal of this study was to review the
clinical efficacy and safety profile of non-interferon based therapies for HCV
treatment. METHODS: We searched the MEDLINE, and abstracts from AASLD and
EASL until May 2011. Studies were selected for clinical trials on direct acting agents
for HCV. Primary endpoints reviewed were Sustained Viral Response (SVR). Toxic-
ity was evaluated as secondary endpoint. Aggregated data were further analyzed to
understand comparative safety and efficacy. RESULTS: Until May 2011, results of
five eligible HCV clinical trials for interferon free regimens were available. Overall,
treatment with combination of protease and polymerase inhibitor showed dra-
matic viral load reduction after 2 weeks of treatment. The combination of PSI-7977
and PSI-938 showed 93% viral clearance after 14 days (n16). The combination of
RG7227 and RG7128 demonstrated 5.1 log reduction in viral load in treatment naive,
and 4.9 log reduction in null responder patients after 14 days of treatment. The
combination of BMS-790052 and BMS 650032 showed 36.3% 24 week SVR in null
responder patients. One study evaluating VX-222 and Telaprevir combination was
discontinued due to viral breakthrough. Several studies are currently on-going
whose data would be available in 2011-2012. CONCLUSIONS:Non-interferon based
therapies have shown impressive viral load reduction in short term studies. How-
ever, more data for SVR, viral breakthrough and resistance is needed to confirm
their safe use in HCV infected population.
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OBJECTIVES: To describe the clinical and economic burden associated with hospi-
tal onset health care facility acquired Clostridium difficile infection (HO-HCFA-CDI)
in European health care facilities (EHCF). METHODS: A systematic review of the
PubMed, EMBASE and infectious disease societies was performed to capture clini-
cal and economic burden of HO-HCFA-CDI in Europe. Included studies were pub-
lished in English between 2000-2010 and had 20 patients with documented CDI
acquired/treated in a EHCF. Data collection was completed by three un-blinded
reviewers using Cochrane Handbook and PRISMA guidelines. The primary out-
comes were mortality, recurrence, length of stay (LOS) and cost related to CDI.
RESULTS: We identified 1138 primary articles and conference abstracts, which
were narrowed to 38 and 30 studies, respectively, after applying eligibility criteria.
Outcomes data were available from only 14 countries, with 47% of studies from UK
institutions. CDI mortality at 30 days ranged from 2% in France to 42% in the UK.
Mortality rates more than doubled from 1999-2004, and continued to rise until 2007,
when reductions were noted in the UK. Recurrent CDI varied from 1% in France to
36% in Ireland; however, equivalent recurrence definitions were not used, which
affects study outcomes. Median length of stay ranged from 8 days in Belgium to 124
days in the UK. The incremental cost of CDI was £4,577 in Ireland and £11,317 in
Germany, after standardization to 2010 GBP. Country-specific averages, weighted
by study sample sizes, ranged from 2.8% to 29.8% for 30-day mortality; 5.9% to
22.6% for recurrence; and, 16.1 to 37.9 days for LOS. CONCLUSIONS: Burden of CDI
in Europe was most commonly described using 30-day mortality, recurrence, LOS
and cost data. Country-specific reporting mandates partly influence the available
data on CDI burden in EHCFs. The continued spread of CDI and resultant healthcare
burden underscores the need for judicious antibiotic use.
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OBJECTIVES: With adherence being a driver of treatment efficacy, we aimed to
systematically assess treatment adherence and efficacy in a disease area impacted
by the rapid emergence of multiple drug resistances as a result of non-adherence,
tuberculosis. We systematically reviewed the literature to qualitatively assess the
impact of directly observed therapy (DOT) versus other treatment modalities (non-
DOT) on adherence and treatment efficacy in patients with tuberculosis.
METHODS: English-language literature indexed in the MEDLINE database (ac-
cessed via PubMed) from January 1, 2000 through November 5, 2010 was systemat-
ically reviewed. Experimental and observational studies with at least 10 patients
and one treatment group receiving a DOT were included and reviewed for adher-
ence and efficacy outcomes. RESULTS: Thirty-seven tuberculosis studies were in-
cluded. Twelve studies reported outcomes for both DOTs and non-DOTs. Six com-
parative studies reported treatment completion; DOT was numerically favored in
5/6 studies, with 3 studies showing significant treatment completion rate benefit in
the DOT group. In Daneil et al., the DOT treatment completion benefit (61.6% DOT,
41.5% non-DOT) paralleled significantly less mortality (9.2% DOT, 19.8% non-DOT)
and greater treatment success (61.6% DOT, 41.5% non-DOT) (p0.001). In Chee et
al., significantly greater treatment completion (89.2% vs. 70.7%) and fewer treat-
ment interruptions (4.0% vs. 12.9%) in the DOT group paralleled fewer deaths (4.2%
vs. 13.1%; p0.001). Only one study showed lower treatment completion and more
deaths for the DOT. However these results were juxtaposed with a higher cure rate
and less treatment default. CONCLUSIONS: DOT has shown specific positive clin-
ical impact by reducing mortality, and increasing treatment success and cure rate
through increased adherence. This suggests the social pressure of health care pro-
fessional involvement in observing therapy administration may be a driver of ad-
herence. The association of both treatment adherence and positive clinical out-
come with DOT may exist in other disease indications.
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OBJECTIVES: The hospital burden and costs of pneumonia, meningitis, and septice-
mia remain high. A retrospective database analysis was conducted for years 2004–
2010 to quantify incidence, case-fatality, length of stay, and cost of hospitalization
from all-cause pneumonia, meningitis, and septicemia in Canada (excluding Quebec).
METHODS: Hospitalizations due to these conditions from 2004–2010 were identi-
fied from a national database in Canada using International Classification of Diseas-
es-10 codes. Statistics Canada provided the population at-risk data for incidence
calculations. A costing model, devised using hospitalization data from Ontario, was
used to estimate disease-specific costs. Results are reported for all age groups
combined. RESULTS: From 2004–2010, hospitalized pneumonia incidence (cases
per 1,000-persons) declined from 3.61 to 3.47, case-fatality rates declined from
12.3% to 11.6%, and average length of hospitalization increased from 9.99 to 10.54
days. Hospitalized meningitis incidence (cases per 100,000-persons) increased
non-monotonically from 4.20 to 4.67, case-fatality rates increased from 5.5% to
6.6%, and average length of hospitalization increased from 12.36 to 12.88 days.
Hospitalized septicemia incidence (cases per 100,000-persons) increased from
74.28 to 82.03, case-fatality rates remained at approximately 26%, and average
length of hospitalization increased from 14.76 to 16.68 days. From 2004–2009, av-
erage total costs (Canadian $) increased from $12,195 to $15,742 for pneumonia,
remained at approximately $19,000 for meningitis, and increased from $22,289 to
$31,019 for septicemia. Incidence patterns for the three conditions differed by age
and gender. CONCLUSIONS: The clinical and economic burden due to all-cause
hospitalized pneumonia, meningitis, and septicemia across all ages combined
have not demonstrated major reductions during the period reviewed and remain
high, particularly for pneumonia. However, the pattern varied by age group. Sub-
stantial savings in costs and hospital resources may accompany prevention of
these conditions by measures aimed at major underlying causes, such as influenza
virus and Streptococcus pneumoniae.
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OBJECTIVES: To provide an overview on the epidemiology of Staphylococcus aureus
(SA) infection in children from North America and Europe. METHODS: A literature
review was conducted using Medline and based on 4 different search strategies to
focus on a children population from birth to 18 years of age and to identify publi-
cations from the last 10 years. RESULTS: A total of 233 abstracts were retrieved,
resulting in the selection of 21 publications. Findings suggest increased incidence
rates of hospital-acquired (HA) SA infections worldwide over time. For instance in
the USA, the increase in the overall incidence of SA infection among children is
significant: from 20.8/1000 admissions in 2002 to 35.8/1000 admissions in 2007, as
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